Nephrogenous cyclic AMP levels in primary hyperparathyroidism

Area of Science:

• Endocrinology
• Nephrology
• Clinical Diagnostics

Background:

• Urinary cyclic adenosine-3',5'-monophosphate (cAMP) measurements have limited clinical utility for diagnosing hyperparathyroidism due to overlap between patient groups.
• Accurate diagnosis of hyperparathyroidism is crucial for effective patient management.

Purpose of the Study:

• To evaluate the diagnostic potential of parathyroid hormone (PTH)-dependent, nephrogenous cAMP in differentiating hyperparathyroid patients from healthy controls.
• To assess whether nephrogenous cAMP levels can overcome the limitations of total urinary cAMP measurements.

Main Methods:

• Collected two-hour urine samples and blood from 23 primary hyperparathyroidism patients and 19 control subjects.
• Calculated nephrogenous cAMP by subtracting filtered cAMP from total urinary cAMP excretion.
• Measured total urinary cAMP excretion in micromols per gram of creatinine.

Main Results:

• Total urinary cAMP excretion was significantly higher in hyperparathyroid patients (6.8 ± 0.5 SE) compared to controls (2.9 ± 0.15), but showed considerable overlap.
• Nephrogenous cAMP levels, expressed as a percentage of total cAMP, were markedly higher in hyperparathyroid patients (72.5 ± 1.8%) than in controls (26.3 ± 4.1%).
• Nephrogenous cAMP levels clearly distinguished between the hyperparathyroid and control groups.

Conclusions:

• Nephrogenous cAMP determination offers a distinct separation between hyperparathyroid patients and normal individuals.
• This method shows promise for improving the diagnostic accuracy of hyperparathyroidism.
• Nephrogenous cAMP measurement may be a valuable tool in the clinical diagnosis of hyperparathyroidism.